Amgen NASDAQ : AMGN pharmaceutical company just released a report stating outstanding performance results for Pivotal Postmenopausal Osteoporosis Trial for denosumab.
Trial reached primary endpoint of Diminishing new vertebral fractures and secondary endpoints of reducing time to first non-vertebral and hip fractures; adverse events similar to placebo. The past president of the National Osteoporosis Foundation was excited." I am particularly excited about these findings because they indicate that denosumab may offer an important new option for patients."
Denosumab is the first fully human monoclonal antibody in late stage clinical development that specifically targets RANK Ligand, an important regulator of osteoclasts (these are the cells that break the bone down). Denosumab is being considered for its ability to inhibit all stages of osteoclast activity through a targeted mechanism. Denosumab is being researched in a range of bone loss illnesses including rheumatoid arthritis, postmenopausal osteoporosis, and cancer treatment-induced bone loss in breast cancer and prostate cancer patients| in prostate cancer and breast cancer patients as well as for its potential to defer bone metastases and stop and treat bone destruction across many stages of cancer.
Osteoporosis is often referred to as the "silent epidemic", osteoporosis is a global problem illness, which is increasing in dominance as the world population both increases and ages. The World Health Organization (WHO) has just claimed osteoporosis as a significant health issue in addition to other major non-communicable diseases. We are dependent on the pharmaceutical industry to help combat this horrendous disease.
According to Amgen the economic burden of osteoporosis is compared to as the "silent epidemi' to that of other major chronic diseases; for example, in the U.S. the costs associated with osteoporosis-related fractures are equivalent to those of cardiovascular disease and asthma. It has been reported that osteoporosis results in more hospital bed-days than stroke, myocardial infarction or breast cancer.
Clinical pharmacist have been researching prescriptions drugs to help patient who experience serious side effects. These products are created almost at the same time as the medications that assist in the treatment of the primary illness. The fact that information is available to help anticipate the possible effects and interactions drugs have with one another is awesome.
These medicines are prescribed to prevent and treat osteoporosis. Some medicines slow the rate of bone loss or increase bone thickness. Minute amounts of new bone growth may diminish the danger of breaking bones. It is important that you take calcium and vitamin D, eat well and exercise when you take osteoporosis prescriptions.
by CF Thompson
